The popular framing — “AI compresses 10-year timelines to 18 months” — describes the front page, not the P&L. 2026 is the pivotal year: the first large-scale Phase III tests of AI-designed drugs.
The two-layer structure
- Front page: AI-designed molecules entering clinical trials. Scientifically unproven at scale; the industry’s ~90% failure rate has not yet been beaten by AI-discovered compounds.
- Back end: the unglamorous operational automation — trial operations, regulatory documentation, manufacturing, pharmacovigilance — which is where AI is actually changing pharma’s cost structure today.
The investable read: underwrite the picks-and-shovels of drug development, not the lottery ticket of the AI-designed molecule — until a Phase III says otherwise.